210 related articles for article (PubMed ID: 31923801)
41. The histone demethylase PHF8 is an oncogenic protein in human non-small cell lung cancer.
Shen Y; Pan X; Zhao H
Biochem Biophys Res Commun; 2014 Aug; 451(1):119-25. PubMed ID: 25065740
[TBL] [Abstract][Full Text] [Related]
42. MTDH mediates trastuzumab resistance in HER2 positive breast cancer by decreasing PTEN expression through an NFκB-dependent pathway.
Du C; Yi X; Liu W; Han T; Liu Z; Ding Z; Zheng Z; Piao Y; Yuan J; Han Y; Xie M; Xie X
BMC Cancer; 2014 Nov; 14():869. PubMed ID: 25417825
[TBL] [Abstract][Full Text] [Related]
43. EPHA5 mediates trastuzumab resistance in HER2-positive breast cancers through regulating cancer stem cell-like properties.
Li Y; Chu J; Feng W; Yang M; Zhang Y; Zhang Y; Qin Y; Xu J; Li J; Vasilatos SN; Fu Z; Huang Y; Yin Y
FASEB J; 2019 Apr; 33(4):4851-4865. PubMed ID: 30620624
[TBL] [Abstract][Full Text] [Related]
44. Posttranscriptional upregulation of HER3 by HER2 mRNA induces trastuzumab resistance in breast cancer.
Li X; Xu Y; Ding Y; Li C; Zhao H; Wang J; Meng S
Mol Cancer; 2018 Aug; 17(1):113. PubMed ID: 30068375
[TBL] [Abstract][Full Text] [Related]
45. Upregulation of mucin4 in ER-positive/HER2-overexpressing breast cancer xenografts with acquired resistance to endocrine and HER2-targeted therapies.
Chen AC; Migliaccio I; Rimawi M; Lopez-Tarruella S; Creighton CJ; Massarweh S; Huang C; Wang YC; Batra SK; Gutierrez MC; Osborne CK; Schiff R
Breast Cancer Res Treat; 2012 Jul; 134(2):583-93. PubMed ID: 22644656
[TBL] [Abstract][Full Text] [Related]
46. Basal/HER2 breast carcinomas: integrating molecular taxonomy with cancer stem cell dynamics to predict primary resistance to trastuzumab (Herceptin).
Martin-Castillo B; Oliveras-Ferraros C; Vazquez-Martin A; Cufí S; Moreno JM; Corominas-Faja B; Urruticoechea A; Martín ÁG; López-Bonet E; Menendez JA
Cell Cycle; 2013 Jan; 12(2):225-45. PubMed ID: 23255137
[TBL] [Abstract][Full Text] [Related]
47. TNFα-Induced Mucin 4 Expression Elicits Trastuzumab Resistance in HER2-Positive Breast Cancer.
Mercogliano MF; De Martino M; Venturutti L; Rivas MA; Proietti CJ; Inurrigarro G; Frahm I; Allemand DH; Deza EG; Ares S; Gercovich FG; Guzmán P; Roa JC; Elizalde PV; Schillaci R
Clin Cancer Res; 2017 Feb; 23(3):636-648. PubMed ID: 27698002
[TBL] [Abstract][Full Text] [Related]
48. Tumor-Associated Fibroblasts Promote HER2-Targeted Therapy Resistance through FGFR2 Activation.
Fernández-Nogueira P; Mancino M; Fuster G; López-Plana A; Jauregui P; Almendro V; Enreig E; Menéndez S; Rojo F; Noguera-Castells A; Bill A; Gaither LA; Serrano L; Recalde-Percaz L; Moragas N; Alonso R; Ametller E; Rovira A; Lluch A; Albanell J; Gascon P; Bragado P
Clin Cancer Res; 2020 Mar; 26(6):1432-1448. PubMed ID: 31699826
[TBL] [Abstract][Full Text] [Related]
49. Transcriptome- and proteome-oriented identification of dysregulated eIF4G, STAT3, and Hippo pathways altered by PIK3CA
Cheng F; Zhao J; Hanker AB; Brewer MR; Arteaga CL; Zhao Z
Breast Cancer Res Treat; 2016 Dec; 160(3):457-474. PubMed ID: 27771839
[TBL] [Abstract][Full Text] [Related]
50. Autophagy-related gene 12 (ATG12) is a novel determinant of primary resistance to HER2-targeted therapies: utility of transcriptome analysis of the autophagy interactome to guide breast cancer treatment.
Cufí S; Vazquez-Martin A; Oliveras-Ferraros C; Corominas-Faja B; Urruticoechea A; Martin-Castillo B; Menendez JA
Oncotarget; 2012 Dec; 3(12):1600-14. PubMed ID: 23307622
[TBL] [Abstract][Full Text] [Related]
51. Elevated expression of histone demethylase PHF8 associates with adverse prognosis in patients of laryngeal and hypopharyngeal squamous cell carcinoma.
Zhu G; Liu L; She L; Tan H; Wei M; Chen C; Su Z; Huang D; Tian Y; Qiu Y; Liu Y; Zhang X
Epigenomics; 2015; 7(2):143-53. PubMed ID: 25496457
[TBL] [Abstract][Full Text] [Related]
52. HER2 overexpression elicits a proinflammatory IL-6 autocrine signaling loop that is critical for tumorigenesis.
Hartman ZC; Yang XY; Glass O; Lei G; Osada T; Dave SS; Morse MA; Clay TM; Lyerly HK
Cancer Res; 2011 Jul; 71(13):4380-91. PubMed ID: 21518778
[TBL] [Abstract][Full Text] [Related]
53. Dynamic microRNA activity identifies therapeutic targets in trastuzumab-resistant HER2
Decker JT; Hall MS; Blaisdell RB; Schwark K; Jeruss JS; Shea LD
Biotechnol Bioeng; 2018 Oct; 115(10):2613-2623. PubMed ID: 29981261
[TBL] [Abstract][Full Text] [Related]
54. Distinct Receptor Tyrosine Kinase Subsets Mediate Anti-HER2 Drug Resistance in Breast Cancer.
Alexander PB; Chen R; Gong C; Yuan L; Jasper JS; Ding Y; Markowitz GJ; Yang P; Xu X; McDonnell DP; Song E; Wang XF
J Biol Chem; 2017 Jan; 292(2):748-759. PubMed ID: 27903634
[TBL] [Abstract][Full Text] [Related]
55. Transcriptomic and ChIP-sequence interrogation of EGFR signaling in HER2+ breast cancer cells reveals a dynamic chromatin landscape and S100 genes as targets.
Nava M; Dutta P; Zemke NR; Farias-Eisner R; Vadgama JV; Wu Y
BMC Med Genomics; 2019 Feb; 12(1):32. PubMed ID: 30736768
[TBL] [Abstract][Full Text] [Related]
56. Epigenetic silencing of TGFBI confers resistance to trastuzumab in human breast cancer.
Palomeras S; Diaz-Lagares Á; Viñas G; Setien F; Ferreira HJ; Oliveras G; Crujeiras AB; Hernández A; Lum DH; Welm AL; Esteller M; Puig T
Breast Cancer Res; 2019 Jul; 21(1):79. PubMed ID: 31277676
[TBL] [Abstract][Full Text] [Related]
57. A preclinical evaluation of the PI3K alpha/delta dominant inhibitor BAY 80-6946 in HER2-positive breast cancer models with acquired resistance to the HER2-targeted therapies trastuzumab and lapatinib.
Elster N; Cremona M; Morgan C; Toomey S; Carr A; O'Grady A; Hennessy BT; Eustace AJ
Breast Cancer Res Treat; 2015 Jan; 149(2):373-83. PubMed ID: 25528022
[TBL] [Abstract][Full Text] [Related]
58. FoxM1 is a downstream target and marker of HER2 overexpression in breast cancer.
Francis RE; Myatt SS; Krol J; Hartman J; Peck B; McGovern UB; Wang J; Guest SK; Filipovic A; Gojis O; Palmieri C; Peston D; Shousha S; Yu Q; Sicinski P; Coombes RC; Lam EW
Int J Oncol; 2009 Jul; 35(1):57-68. PubMed ID: 19513552
[TBL] [Abstract][Full Text] [Related]
59. Histone demethylase PHF8 accelerates the progression of colorectal cancer and can be regulated by miR-488 in vitro.
Lv Y; Shi Y; Han Q; Dai G
Mol Med Rep; 2017 Oct; 16(4):4437-4444. PubMed ID: 28765946
[TBL] [Abstract][Full Text] [Related]
60. A novel tumor suppressor ZBTB1 regulates tamoxifen resistance and aerobic glycolysis through suppressing
Zhang P; Yang Y; Qian K; Li L; Zhang C; Fu X; Zhang X; Chen H; Liu Q; Cao S; Cui J
J Biol Chem; 2020 Oct; 295(41):14140-14152. PubMed ID: 32690611
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
